Targets › ERCC3
1 program from 1 company in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2027.
ATP-dependent 3'-5' DNA helicase/translocase. Binds dsDNA rather than ssDNA, unzipping it in a translocase rather than classical helicase activity. (UniProt, P19447)
Open in Phaseline: the race on ERCC3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| M.D. Anderson Cancer Center | Trabectedin Alkylating agent - binds DNA and inhibits transcription, particularly affecting transcript | ERCC2, ERCC3 | Phase 2 | Uterine Leiomyosarcoma; Soft Tissue Sarcomas | Dec 2027 |
Uterine Leiomyosarcoma (1) Soft Tissue Sarcomas (1)
mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.